MAPK14 and fatty liver disease: We showed that SB203580 treatment or MAPK14 knockdown effectively reduced the phosphorylation of p38α MAPK and promoted the PA-mediated hepatic steatosis, as analyzed by neutral lipid stained liver cells and direct measurement of hepatic TG and PL (Figures 5a–d).